SKSlobodanka Ostojić Kolonić

Slobodanka Ostojić Kolonić

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Slobodanka Ostojić Kolonić has a total of 98 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • First-Line Therapy for Nodal T-cell Non-Hodgkin Lymphomas: an Unmet Need in Hematology

    by Vibor Milunović, Inga Mandac Smoljanović, Martina Bogeljić Patekar, Viktor Zatezalo, Marin Kursar, Delfa Radić-Krišto, Slobodanka Ostojić Kolonić, Slavko Gašparov

    Purposeof Review The main aim of this review is to summarize first-line therapy of nodal T-cell non-Hodgkin lymphoma. Recent Findings Current treatment with CHOP chemotherapy results in poor outcomes in the majority of patients. However, there are advances within the field. First breakthrough is the ECHELON-2 trial which showed that the addition of brentuximab vedotin improves outcomes in anaplastic large cell lymphoma. However, other types of peripheral T-cell non-Hodgkin lymphoma were underrepresented with optimal treatment not known. Second breakthrough is an increase of autologous stem cell transplantation usage in the first complete metabolic remission, except in ALK + anaplastic large cell lymphoma, offering better disease control. Summary Despite advances in the field, CHOP remains the standard treatment for the majority of these lymphomas, but multiple trials are underway with the aim to improve this unmet need in hematology and, hopefully, leading us to a new era in the treatment of peripheral T-cell lymphomas.


  • Open Access

    Clinical Dilemmas in the Treatment of Elderly Patients Suffering from Hodgkin Lymphoma: A Review

    by Vibor Milunović, Ida Hude, Goran Rinčić, Davor Galušić, Aron Grubešić, Marko Martinović, Nika Popović, Sunčana Divošević, Klara Brčić, Marin Međugorac, et al.

    Elderly patients make up a significant number of cases of newly diagnosed Hodgkin lymphoma. However, unlike in young patients, the outcomes of elderly patients are poor, and they are under-represented in phase III trials. Prior to treatment initiation, geriatric assessment should ideally be performed to address the patient’s fitness and decide whether to pursue a curative or palliative approach. The ABVD regimen is poorly tolerated in unfit patients, with high treatment-related mortality. Alternative chemotherapy approaches have been explored, with mixed results obtained concerning their feasibility and toxicity in phase II trials. The introduction of brentuximab vedotin-based regimens led to a paradigm shift in first- and further-line treatment of elderly Hodgkin lymphoma patients, providing adequate disease control within a broader patient population. As far as checkpoint inhibitors are concerned, we are only just beginning to understand the role in the treatment of this population. In relapsed/refractory settings there are few options, ranging from autologous stem cell transplantation in selected patients to pembrolizumab, but unfortunately, palliative care is the most common modality. Importantly, published studies are frequently burdened with numerous biases (such as low numbers of patients, selection bias and lack of geriatric assessment), leading to low level of evidence. Furthermore, there are few ongoing studies on this topic. Thus, elderly Hodgkin lymphoma patients are hard to treat and represent an unmet need in hematologic oncology. In conclusion, treatment needs to be personalized and tailored on a case-by-case basis. In this article, we outline treatment options for elderly Hodgkin lymphoma patients.


  • CD4+/CD57+/CD69+ T lymphocytes and CD14+ dendritic cells accumulate in advanced follicular lymphoma

    by Paula Gršković, Suzana Hančić, Snježana Dotlić, Maja Matulić, Slobodanka Ostojić Kolonić, Slavko Gašparov, Mara Dominis, Petra Korać


  • Open Access

    Macrophage Infiltration Correlates with Genomic Instability in Classic Hodgkin Lymphoma

    by Suzana Hančić, Paula Gršković, Slavko Gašparov, Slobodanka Ostojić Kolonić, Mara Dominis, Petra Korać

    Hodgkin lymphoma (HL) is a biologically diverse group of lymphoid tumors, which accounts for 1% of all de novo neoplasms in the world’s population. It is divided into two main groups: the more common classic Hodgkin lymphoma (cHL) and the less common nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). cHL is further divided into four subtypes, which differ in morphology and the contents of tumor microenvironment. Macrophages are one of the components of tumor microenvironment known to contribute to creating an immunosuppressive microenvironment, which inhibits the activity of cells expressing granzyme B against tumor cells, even when tumor cells are infected with Epstein–Barr virus (EBV). Our research aimed to explore the association between the specific contents of tumor microenvironment and the genetic anomalies in tumor cells. The presence and the relative percentage of cytotoxic T lymphocytes and macrophages was detected by immunohistochemical staining of the antigens specific for certain cell populations. Fluorescent in situ hybridization was used to detect anomalies in the genome of tumor cells and in situ hybridization was used to detect the presence of EBV. Our results show an association between the number of CD163+ macrophages and the number of TP53 copies or BCL6 gene translocation. Patients who had a higher number of CD163+ macrophages infiltrating tumor tissue and three or higher number of copies of TP53 showed poorer survival. We conclude that the presence of macrophages may contribute to genetic instability in cHL, which drives the progression of cHL and decreases survival of the patients.


  • The fading star of obinutuzumab-chlorambucil regimen in patients with comorbidities with chronic lymphocytic leukemia – are we ready for chemo-free immunotherapy approach?

    by Vibor Milunović, Karla Mišura Jakobac, Inga Mandac Rogulj, Marko Martinović, Delfa Radić-Krišto, Slobodanka Ostojić Kolonić

    Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries occurring typically in elderly patients. These patients often present with comorbidities limiting treatment optio...


  • Open Access

    Neoangiogenesis and microvascular density in myelodysplastic syndrome – a single center experience

    by Anita Skrtic, Njetocka Gredelj-Simec, Ika Kardum-Skelin, Eva Lovric, Darija Muzinic, Slavko Gasparov, Slobodanka Ostojic Kolonic

    Angiogenesis has a significant part in the pathogenesis of hematological malignancies, such as leukemia and myelodysplastic syndromes (MDS). We evaluated the relationship between morphometric, morphological and clinical features of MDS. Blood vessels of 31 newly diagnosed MDS bone marrow biopsies were immunohistochemically analyzed using CD34 and compared with 8 controls and 13 chronic myelomonocytic leukemias (CMML). MDS were categorized into three risk groups: low-, intermediate- and high-risk MDS. Microvascular density (MVD) and major and minor axis length were analyzed using digital image analysis. Overall, MDS had significantly higher MVD and lower minor axis values than the control group and CMML. High-risk MDS had significantly higher MVD compared to the controls, while all MDS risk groups had lower minor axis values than the control group. Increased minor and major axis values were prognostic predictors of shorter overall survival in all MDS risk groups and CMML patients. In conclusion, angiogenesis presents one of the essential factors in MDS pathogenesis and progression characterized by descriptive marrow microvascular network transformation. The size-related features are powerful indicators of survival in MDS patients.

  • Open Access

    FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: Another player in the town?

    by Vibor Milunović, Karla Mišura Jakobac, Marin Kursar, Inga Mandac Rogulj, Slobodanka Ostojić Kolonić

    ECHELON‐1 study is a randomized open‐labeled controlled trial investigating whether addition of brentuximab vedotin to chemotherapy offers benefit over the standard chemotherapy regimen in advanced Hodgkin lymphoma. After a median follow‐up of 24.6 months, it has met its primary endpoint the reduction of modified progression‐free survival being 23 percent. However, the beneficial effects have not been seen across all subgroups leading to further questions. The main aim of this review is to tackle these questions to provide the reader with in‐depth insight of pros and cons of this novel, promising but ultimately controversial regimen.


    • 12 January 2016
      • Vol. 137, 276-82

    [AUTOLOGOUS STEM CELL TRANSPLANTATION IN REFRACTORY OR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA - A SINGLE CENTRE EXPERIENCE].

    by Vibor Milunović, Martina Bogeljić Patekar, Vinko Roso, Viktor Zatezalo, Bojana Aćamović Stipinović, Karla Mišura Jakobac, Njetočka Gredelj Šimec, Delfa Radić-Krišto, Ana Planinc-Peraica, Slobodanka Ostojić Kolonić

    Autologous stem cell transplantation represents the gold standard in chemosensitive diffuse B large cell lymphoma in relapse or in refractory setting. The aim of this study was to present the outcome of peripheral autologous stem cell transplantation in patients with refractory or relapsed diffuse large B cell lymphoma. We retrospectively analysed the data of 62 patients, who underwent this procedure for the period 2000-2013. The majority of patients (71%) were treated with miniBEAM salvage chemotherapy and all received BEAM myeloablative protocol followed by the stem cell reinfusion. The overall response rate for autologous transplantation was 75.8%. Median overall survival was 37.2 months. Median event-free survival was 16.9 months. Factors associated with overall survival were state of disease prior to salvage chemotherapy, chemosensitivity of disease, International prognostic index, disease activity at the relapse, response to autologous transplantation and post-transplantation radiotherapy. The use of rituximab was not significantly correlated to the outcome. In this patient group autologous stem cell transplantation was found to be effective in achieving remission and survival showing the adequate role of this procedure in this clinical setting. We stress out that autologous stem cell transplantation was effective in 32.5% patients with chemorefractory disease after salvage therapy.

  • Left ventricular mycotic mass and diffuse mycotic myocarditis in a patient with hemophagocytic syndrome – case report

    by Matija Markovic, Njetocka Gredelj Simec, Tomislav Letilovic, Ana Planinc-Peraica, Slobodanka Ostojic Kolonic

    • 1 March 2013
      • Vol. 67  (1) , 3-11

    [Diagnostic approach and treatment of immune thrombocytopenia in adults].

    by Slobodanka Ostojić Kolonić, Martina Bogeljić Patekar, Vibor Milunović

    The aim of this review is to provide the Croatian medical public with novel insights into the definition, pathogenesis, diagnostic algorithms and treatment approaches to immune thrombocytopenia (ITP) in adults. Recently, primary ITP has been uniformly defined as an autoimmune disorder characterized by an isolated platelet count lower than 100 x 10(9)/L without preexisting disease or conditions, which could lead to thrombocytopenia. The recognition of primary and secondary ITP is important because they require different treatment strategies. In secondary ITP, therapeutic approach oriented towards the underlying disorder. Unlike childhood onset ITP, which is a self-limited condition with high rates of spontaneous remissions, adulthood onset ITP usually has chronic course. Previously, the pathogenesis of ITP was considered to be immune mediated destruction of platelets in liver and spleen, while recent findings have shown a novel pathophysiological pathway based on the inhibition of thrombopoiesis, leading to novel treatment approaches. The diagnosis of ITP is based on exclusion of the possible underlying causes of thrombocytopenia and consists of simple diagnostic procedures. The decision to treat ITP should be based individually: platelets count (lower than 30 x 10(9)/L), various bleeding risk factors and patient's preference. The use of corticosteroids is the mainstay of first line therapy. Two most commonly used corticosteroids are prednisone and dexamethasone. Prednisone is administered continuously, while dexamethasone is applied in cycles. Due to the lack of randomized clinical trials, it is not possible to recommend certain class of corticosteroid therapy. Another two agents used as first line therapy in case of corticosteroid refractoriness or the need of rapid platelet elevation, are intravenous immunoglobulins and anti-D immunoglobulin (anti-D is not approved in Europe). They are characterized by rapid onset of platelet recovery and low long-term remission rates. Until recently, splenectomy, with adequate infectious and thromboprophylaxis, was the therapy of choice in patients who did not respond to corticosteroids due to high long-term remission rates and low relapse rates. This procedure can be offered to a younger patient without significant comorbidities after the first year of ITP duration. With advances in the understanding of ITP pathogenesis, a new class of drug has been established: thrombopoietin agonists (TPO). Eltrombopag and romiplostim, the TPO agonists currently approved for the management of ITP in patients who failed the first line therapy and are not suitable for splenectomy, are only two agents that have shown benefits in large clinical randomized trials. They are characterized by a high response rate and appropriate safety profile, but the need for continuous use, a high relapse rate after therapy withdrawal, and price limit their use in everyday practice. TPO agonists represent an appropriate treatment choice in patients who have relapse after splenectomy. Another agent, often used in everyday clinical practice, is rituximab with high response and relapse rates. Its use is based on small studies, and due to the lack of clinical randomized controlled trials, rituximab is not approved by the leading medical agencies for this indication. As shown in this review article, our understanding and therapy for ITP has improved, but further research is needed to implement evidence-based therapy in clinical practice.